Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 1
2011 1
2012 1
2013 6
2014 5
2015 9
2016 7
2017 11
2018 10
2019 8
2020 19
2021 18
2022 21
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Echinococcosis: Advances in the 21st Century.
Wen H, Vuitton L, Tuxun T, Li J, Vuitton DA, Zhang W, McManus DP. Wen H, et al. Among authors: vuitton l. Clin Microbiol Rev. 2019 Feb 13;32(2):e00075-18. doi: 10.1128/CMR.00075-18. Print 2019 Mar 20. Clin Microbiol Rev. 2019. PMID: 30760475 Free PMC article. Review.
Busting the myth of methotrexate chronic hepatotoxicity.
Di Martino V, Verhoeven DW, Verhoeven F, Aubin F, Avouac J, Vuitton L, Lioté F, Thévenot T, Wendling D. Di Martino V, et al. Among authors: vuitton l. Nat Rev Rheumatol. 2023 Feb;19(2):96-110. doi: 10.1038/s41584-022-00883-4. Epub 2022 Dec 23. Nat Rev Rheumatol. 2023. PMID: 36564450 Review.
JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. Jamilloux Y, et al. Among authors: vuitton l. Autoimmun Rev. 2019 Nov;18(11):102390. doi: 10.1016/j.autrev.2019.102390. Epub 2019 Sep 11. Autoimmun Rev. 2019. PMID: 31520803 Review.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Among authors: vuitton l. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy.
Charbit-Henrion F, Haas M, Chaussade S, Cellier C, Cerf-Bensussan N, Malamut G; Contributors from the AUTOIMMUNE ENTEROPATHY WORKING GROUP; Khater S, Khiat A, Cording S, Parlato M, Dragon-Durey MA, Beuvon F, Brousse N, Terris B, Picard C, Fusaro M, Rieux-Laucat F, Stolzenberg MC, Jannot AS, Mathian A, Allez M, Malphettes M, Fieschi C, Aubourg A, Zallot C, Roblin X, Abitbol V, Belle A, Wils P, Cheminant M, Matysiak-Budnik T, Vuitton L, Pouderoux P, Abramowitz L, Castelle M, Suarez F, Hermine O, Ruemmele F, Mouthon L. Charbit-Henrion F, et al. Among authors: vuitton l. Clin Gastroenterol Hepatol. 2023 May;21(5):1368-1371.e2. doi: 10.1016/j.cgh.2022.07.030. Epub 2022 Aug 6. Clin Gastroenterol Hepatol. 2023. PMID: 35944833 Free PMC article. No abstract available.
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID.
Amiot A, Chaibi S, Bouhnik Y, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Le Berre C, Dib N, Brixi H, Painchart C, Plastaras L, Altwegg R, Fumery M, Caillo L, Laharie D, Nachury M; GETAID-patient experience study group. Amiot A, et al. Among authors: vuitton l. J Crohns Colitis. 2023 Oct 20;17(9):1418-1425. doi: 10.1093/ecco-jcc/jjad060. J Crohns Colitis. 2023. PMID: 36988620 Free article.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L. Fumery M, et al. Among authors: vuitton l. Aliment Pharmacol Ther. 2023 Feb;57(4):426-434. doi: 10.1111/apt.17358. Epub 2022 Dec 19. Aliment Pharmacol Ther. 2023. PMID: 36534763
112 results